1 St John's Institute of Dermatology, King's College London School of Medicine; NIHR Biomedical Research Centre; and FOCIS Centre of Excellence at King's College London London SE1 9RT UK.
In just 10 years from its discovery in 2000, interleukin-23 has quickly moved from being recognized as a pro-inflammatory cytokine to a key player and potential therapeutic target in psoriasis.